Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review [PDF]
Dermatology and Therapy, 2023 Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the treatment of androgenetic alopecia since early 2000.
Omar Yaxmehen Bello-Chavolla +1 more
exaly +5 more sources
The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia [PDF]
Asian Journal of Urology, 2018 Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including ...
Eric H Kim
exaly +4 more sources
5-alpha reductase inhibitors use in prostatic disease and beyond. [PDF]
Transl Androl Urol, 2023 5-alpha reductase inhibitors (5-ARIs) are commonly used and widely available, with benefits observed from their effect on androgen signalling. Their effect relies on the inhibition of the 5-alpha reductase enzyme which aids in the conversion of testosterone to dihydrotestosterone.
Chislett B +5 more
europepmc +5 more sources
Antipsychotic-Like Properties of 5-alpha-Reductase Inhibitors [PDF]
Neuropsychopharmacology, 2008 Recent evidence indicates that neuroactive steroids may participate in the pathogenesis of schizophrenia spectrum disorders, yet the mechanisms of this involvement are elusive.
Bortolato M +7 more
core +6 more sources
Contraindicated use of 5-alpha-reductase inhibitors in women. [PDF]
Br J Clin Pharmacol, 2017 Item does not contain ...
Teichert M +2 more
europepmc +7 more sources
May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications? [PDF]
Med Hypotheses, 2020 COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females.
Adamowicz J, Juszczak K, Drewa T.
europepmc +2 more sources
Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome [PDF]
Skin Appendage Disorders, 2017 Postfinasteride syndrome (PFS) is a term recently coined to characterize a constellation of reported undesirable side effects described in postmarketing reports and small uncontrolled studies that developed during or after stopping finasteride treatment,
Shapiro, Jerry +3 more
core +3 more sources
Early embryonic exposure of freshwater gastropods to pharmaceutical 5-alpha-reductase inhibitors results in a surprising open-coiled "banana-shaped" shell. [PDF]
Sci Rep, 2019 In vertebrates, the steroidogenesis enzyme 5α-reductase converts testosterone to the more potent androgen 5α-dihydrotestosterone. Homologues of 5α-reductase genes have been identified in molluscs.
Baynes A +6 more
europepmc +2 more sources
Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection. [PDF]
BiomoleculesConcerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection.
Morote J +10 more
europepmc +2 more sources
Clinical Breast Cancer, 2019 OBJECTIVE: 5-alpha reductase inhibitors (5ARIs) decrease the androgen levels in vivo and are currently used for the treatment of benign prostatic hyperplasia (BPH) in men.
Qinghua Fang, Kutty Selva Nandakumar
exaly +2 more sources